BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Masetti C, Pugliese N, Aghemo A, Viganò M. Safety of current antiviral drugs for chronic hepatitis B. Expert Opin Drug Saf 2022. [PMID: 35209776 DOI: 10.1080/14740338.2022.2045271] [Reference Citation Analysis]
2 Facciorusso A, Cincione I, Sacco R. Comparison of Tenofovir and Entecavir in the Prevention of Hepatocellular Carcinoma Occurrence in Patients with Chronic Hepatitis B. Liver Cancer 2021;10:285-6. [PMID: 34239814 DOI: 10.1159/000512780] [Reference Citation Analysis]
3 Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. Int J Mol Sci 2021;22:1456. [PMID: 33535672 DOI: 10.3390/ijms22031456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Reference Citation Analysis]
5 Choi J, Lim YS. Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. Kaohsiung J Med Sci 2021;37:262-7. [PMID: 33502828 DOI: 10.1002/kjm2.12364] [Reference Citation Analysis]
6 Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study. Front Med (Lausanne) 2021;8:637126. [PMID: 33791326 DOI: 10.3389/fmed.2021.637126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lee JS, Lee HW, Lim TS, Shin HJ, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. Cancers (Basel) 2021;13:5892. [PMID: 34885000 DOI: 10.3390/cancers13235892] [Reference Citation Analysis]
8 Yuan J, Peng Y, Hao FB, Wang YQ, Wang CR, Zhong GC. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY) 2021;13:7147-65. [PMID: 33658397 DOI: 10.18632/aging.202573] [Reference Citation Analysis]
9 Huang ZH, Lu GY, Qiu LX, Zhong GH, Huang Y, Yao XM, Liu XH, Huang SJ, Wu T, Yuan Q, Wang YB, Su YY, Zhang J, Xia NS. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer 2022;22:287. [PMID: 35300634 DOI: 10.1186/s12885-022-09413-7] [Reference Citation Analysis]
10 Lu H, Yi W, Sun F, Zeng Z, Zhang L, Li M, Xie Y. Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy. Biosafety and Health 2021;3:190-6. [DOI: 10.1016/j.bsheal.2021.05.001] [Reference Citation Analysis]
11 Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:402-12. [PMID: 34157830 DOI: 10.3350/cmh.2021.0179] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]
13 Nahon P, Vo Quang E, Ganne-Carrié N. Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control. J Clin Med 2021;10:353. [PMID: 33477752 DOI: 10.3390/jcm10020353] [Reference Citation Analysis]
14 Tseng CH, Hsu YC, Nguyen MH. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply. Lancet Gastroenterol Hepatol 2021;6:87-8. [PMID: 33444533 DOI: 10.1016/S2468-1253(20)30395-2] [Reference Citation Analysis]
15 Li Y, Zhou T, Cheng X, Li D, Zhao M, Zheng WV. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3. Bioengineered 2022;13:4730-43. [DOI: 10.1080/21655979.2022.2031408] [Reference Citation Analysis]
16 Choi WM, Choi J, Wong GL, Han S, Lim YS. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B. Lancet Gastroenterol Hepatol 2021;6:87. [PMID: 33444532 DOI: 10.1016/S2468-1253(20)30372-1] [Reference Citation Analysis]
17 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Inoue J, Sato K, Ninomiya M, Masamune A. Envelope Proteins of Hepatitis B Virus: Molecular Biology and Involvement in Carcinogenesis. Viruses 2021;13:1124. [PMID: 34208172 DOI: 10.3390/v13061124] [Reference Citation Analysis]
19 Motomura T, Amirneni S, Diaz-Aragon R, Faccioli LAP, Malizio MR, Coard MC, Kocas-Kilicarslan ZN, Frau C, Haep N, Ostrowska A, Florentino RM, Soto-Gutierrez A. Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target. J Pers Med 2021;11:619. [PMID: 34208839 DOI: 10.3390/jpm11070619] [Reference Citation Analysis]